OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
PharmTech
Picture: PharmTech
On October 20, 2026, OpenAI acquired Orchestra Bio, a software platform that biopharmaceutical teams use to coordinate drug development programs, the company announced.1 OpenAI said it will combine Orchestra’s team and technology with Rosalind, its suite of AI models and tools for life sciences research. The company says the goal is to help scientists make discoveries and manage the work needed to turn them into approved treatments. Financial terms were not disclosed. The deal extends OpenAI’s life sciences work beyond scientific reasoning and into program execution.1 Rosalind currently has 2 parts. GPT-Rosalind is a model designed to help scientists reason through biology and chemistry questions. Rosalind Workbench connects those capabilities to scientific tools and data so researchers can analyze results and plan experiments.
Also carried by Securities.io, The Information, PharmTech.com, Dealroom.
This report was first published by PharmTech. What you see here is a brief excerpt. The full text is theirs.
Continue reading at PharmTech
